European Journal of Clinical Pharmacology

, Volume 59, Issue 10, pp 767–773 | Cite as

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000

  • Andrew Boshier
  • Lynda V. Wilton
  • Saad A. W. Shakir
Pharmacoepidemiology and Prescription

Abstract

Background

Bupropion (Zyban) is the first new pharmacological treatment for smoking cessation to be introduced since nicotine replacement therapy. In smoking cessation trials, it has been associated with minimal side effects. A range of suspected adverse drug reactions (ADRs) were reported via the spontaneous reporting system following its use in smoking cessation.

Aim

To examine the safety of bupropion used in general medical practice in England as a treatment for cessation of smoking.

Objectives

To quantify the incidence of events that were reported for patients prescribed bupropion; and to identify any previously unrecognised ADRs.

Methods

A post-marketing observational cohort study was conducted using the methodology of prescription-event monitoring (PEM). Exposure data were derived from the first prescription dispensed for patients whose prescription details were processed by the Prescription Pricing Authority in August 2000. Outcome data were derived from ‘green form’ questionnaires (GFs) sent to general practitioners (GPs) at least 6 months following the first prescription issued. Incidence densities (IDs) were calculated for events reported per 1000 weeks of patient treatment and ID differences between time periods analysed. Events of interest were followed up by postal questionnaire sent to GPs. All-cause and condition-specific mortality up to 12 weeks after starting bupropion were compared through indirect standardisation between the PEM cohort and Cancer Prevention Study-II (USA) (CPS-II) data.

Results

GF response rate was 48.1%, with 11,735 GFs containing useful data – of these patients, 5695 (48.5%) were male (median age 47 years, range 16–88 years) and 6009 (51.2%) were female (median age 47 years, range 16–87 years). Age was recorded for 4092 (34.9%) of the cohort of 11,735 after follow-up. There were 566 events in 350 patients reported by GPs as ADRs to bupropion. GPs reported 10,200 reasons for stopping bupropion among 9056 patients. The highest ranked clinical events (by ID for weeks 1–6 of treatment) were; ‘insomnia’ (n=308), ‘nausea/vomiting’ (n=243) and ‘dizziness’ (n=185). Bupropion was taken in the first trimester of 12 pregnancies and the outcome ascertained in eight cases – five live births (no congenital abnormalities reported), two therapeutic terminations and one intrauterine death (no further details). The standardised mortality ratio (SMR) for all-cause mortality up to 12 weeks after starting bupropion was 0.77 (95% CI: 0.42, 1.28).

Conclusion

This study describes the safety profile of bupropion (Zyban) as used in the community; a small number of adverse events were reported that were not included on the SmPC. For many events, nicotine withdrawal was a confounding factor. SMR calculations did not provide evidence for a higher rate of mortality (either all-cause or condition-specific) in the PEM cohort relative to smokers from the CPS-II cohort in the USA. While reassuring, the SMR should be interpreted in context with results from other studies on bupropion when used for smoking cessation.

Keywords

Smoking cessation Bupropion (Zyban) Prescription-event monitoring (PEM) 

References

  1. 1.
    McRobbie H (May 2001) Zyban: non-nicotine aid to smoking cessation. Prescriber 12:23–28Google Scholar
  2. 2.
    GlaxoSmithKline (2002) Summary of product characteristics for Wellbutrin SR (bupropion). GlaxoSmithKline, October 2002Google Scholar
  3. 3.
    GlaxoSmithKline (2000) Summary of product characteristics for Zyban (bupropion). GlaxoSmithKline, June 2000Google Scholar
  4. 4.
    West R, McNeill A, Raw M (2000) Smoking cessation guidelines for health professionals: an update. Thorax 55:987–999PubMedGoogle Scholar
  5. 5.
    Monthly Index of Medical Specialties (MIMS) (2000) Haymarket Medical Ltd; July issueGoogle Scholar
  6. 6.
    Callum C (1998) The UK Smoking Epidemic: Deaths in 1995. Health Education AuthorityGoogle Scholar
  7. 7.
    Jorenby DE, Leischow SJ, Nides MA, et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedGoogle Scholar
  8. 8.
    Hurt RD, Sachs DP, Glover ED, et al (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202PubMedGoogle Scholar
  9. 9.
    Ascher JA, Cole JO, Colin JN, et al (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401PubMedGoogle Scholar
  10. 10.
    Tashkin DP, Kanner R, Bailey W, et al (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571–1575CrossRefPubMedGoogle Scholar
  11. 11.
    UK Medicines Control Agency (2000) Statement from a safety update for bupropion (Zyban). Pharm J 265:712Google Scholar
  12. 12.
    Shakir S (2002) Prescription-event monitoring. In: Mann RD, Andrews E (eds) Pharmacovigilance. John Wiley & Sons Ltd UK, pp 333–344Google Scholar
  13. 13.
    Shakir S (2000) Causality assessment in PEM. In house, Drug Safety Research UnitGoogle Scholar
  14. 14.
    WHO (1993) International ethical guidelines for biomedical research involving human subjects. CIOMS/WHO, GenevaGoogle Scholar
  15. 15.
    Royal College of Physicians of London (1996) Guidelines on the practice of ethical committees in medical research involving human subjectsGoogle Scholar
  16. 16.
    Multi-Centre Research Ethics Committees Guidance Notes (2000) Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary Appendix C: 21Google Scholar
  17. 17.
    Thun MJ, Day-Lally C, Myers DG, et al (1997) Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). In: Changes in cigarette-related disease risks and their implication for prevention and control. Smoking and tobacco control monograph 8. Bethesda, Maryland: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute 305–382Google Scholar
  18. 18.
    GlaxoSmithKline (2002) Summary of Product Characteristics for Zyban (bupropion), GlaxoSmithKline, 9 July 2002Google Scholar
  19. 19.
    Key C, Layton D, Shakir SAW (2002) Results of a postal survey of the reasons for non-response by doctors in a prescription-event monitoring study of drug safety. Pharmacoepidemiol Drug Saf 11:143–148CrossRefPubMedGoogle Scholar
  20. 20.
    American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DCGoogle Scholar
  21. 21.
    Hughes JR (2001) Why does smoking so often produce dependence? A somewhat different view. Tobacco Control 10:62–64CrossRefPubMedGoogle Scholar
  22. 22.
    Hughes JR (1992) Tobacco withdrawal in self-quitters. Consult Clin Psychol 60:689–697PubMedGoogle Scholar
  23. 23.
    Dunner DL, Zisook S, Billow AA, et al (1998) A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59:366–373PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Andrew Boshier
    • 1
    • 2
  • Lynda V. Wilton
    • 1
    • 2
  • Saad A. W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK

Personalised recommendations